Trump Administration Expands TrumpRx with Generic Medications
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 34 minutes ago
0mins
Should l Buy LLY?
Source: CNBC
- Platform Expansion: The Trump administration announced the addition of over 600 generic medications to the TrumpRx website, aiming to lower prescription drug costs in the U.S. by providing transparent pricing and enhancing consumer choice.
- New Tools Launched: The platform now features tools that connect patients with the lowest-priced pharmacies in their area and offers home delivery options for prescriptions, improving user experience and facilitating easier access to medications.
- Partnerships Established: The administration is partnering with industry players like Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx to promote direct-to-consumer drug sales, ensuring price transparency for consumers.
- User Engagement and Savings: Since its launch, TrumpRx has recorded over 10 million visits and saved Americans more than $400 million, although it remains unclear if all patients will benefit from this platform compared to traditional purchasing methods.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1004.920
Low
950.00
Averages
1192
High
1500
Current: 1004.920
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Administration Expands TrumpRx with Generic Medications
- Platform Expansion: The Trump administration announced the addition of over 600 generic medications to the TrumpRx website, aiming to lower prescription drug costs in the U.S. by providing transparent pricing and enhancing consumer choice.
- New Tools Launched: The platform now features tools that connect patients with the lowest-priced pharmacies in their area and offers home delivery options for prescriptions, improving user experience and facilitating easier access to medications.
- Partnerships Established: The administration is partnering with industry players like Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx to promote direct-to-consumer drug sales, ensuring price transparency for consumers.
- User Engagement and Savings: Since its launch, TrumpRx has recorded over 10 million visits and saved Americans more than $400 million, although it remains unclear if all patients will benefit from this platform compared to traditional purchasing methods.
See More
US Supreme Court Rejects Eli Lilly's Challenge to Whistleblower Law
- Legal Challenge Denied: The US Supreme Court's refusal to hear Eli Lilly's challenge to the whistleblower law could significantly impact compliance costs and legal risks within the pharmaceutical industry.
- Origin of the Case: This challenge originated in 2014 when pharmacist and lawyer Ronald Streck accused Lilly of failing to pay full drug rebates to Medicaid, resulting in a $183 million judgment, highlighting the regulatory scrutiny faced by pharmaceutical companies.
- Legal Consequences: With the Supreme Court's decision, Lilly may encounter an increase in whistleblower lawsuits, raising its legal compliance costs and potentially affecting its future financial performance and market confidence.
- Industry Implications: This ruling may prompt other pharmaceutical companies to pay closer attention to compliance issues, particularly regarding drug pricing and rebate transparency, thereby influencing operational models and competitive strategies across the industry.
See More
Healthcare Stocks Rise Slightly on NYSE
- Healthcare Index Increase: The NYSE Healthcare Index rose by 0.4% on Monday afternoon, indicating a rebound in market confidence towards the healthcare sector, likely influenced by optimistic investor expectations regarding future healthcare policies.
- Market Trend Analysis: The upward trend in healthcare stocks suggests that despite economic uncertainties, investors remain bullish on the long-term growth potential of the healthcare industry, particularly in the context of new drug development and an aging population.
- Improved Investor Sentiment: The stable performance of healthcare stocks has led to improved investor sentiment, which may result in increased capital inflows into the sector, further driving the rise in healthcare stocks.
- Industry Outlook: The ongoing growth in the healthcare sector is likely to attract more investor attention, especially with the dual support of policy backing and technological innovation, indicating that more investment opportunities are expected to emerge in the future.
See More
Pharmaceutical Giants' Acquisition Targets Analysis
- Viking Therapeutics Highlights: Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, has enrolled over 4,500 patients in Phase 3 ahead of schedule, with oral formulations achieving a 12.2% body weight reduction in 13 weeks, making it a strategically attractive acquisition target with a market cap of $3.69 billion and $706 million in cash.
- Scholar Rock's Market Potential: Scholar Rock's muscle-targeted therapy apitegromab is expected to launch in Europe in H2 2026, already partnered with Novo Nordisk, with a market cap of $5.55 billion and an analyst target price of $57.73, highlighting its significance in the GLP-1 landscape.
- Verve Therapeutics' Outlook: Verve Therapeutics' VERVE-102, a single-dose gene-editing PCSK9 therapy, achieved a 53% mean LDL-C reduction in the Heart-2 Phase 1b trial, with Lilly holding an opt-in that may lead to outright acquisition, showcasing its potential in cardiovascular disease treatment.
- Market Competition Dynamics: Eli Lilly and Novo Nordisk are aggressively acquiring early-stage therapeutics to maintain GLP-1 market dominance, with Lilly's recent four acquisitions indicating its expansion strategy, despite Novo facing pricing pressures and declining sales challenges.
See More
Three Undervalued Stocks to Consider Now
- Pfizer's Current Status: Pfizer's stock is currently priced around $25, and despite a 1% increase this year, investors have seen a 37% decline over the past five years due to slowing growth and patent expirations; however, the company is actively expanding its pipeline through acquisitions like Metsera, which could improve future performance.
- Novo Nordisk's Challenges: Novo Nordisk's GLP-1 drugs, Wegovy and Ozempic, have been approved and are generating significant revenue, but rising competition has led to a 4% decline in sales in the first quarter; nevertheless, strong demand for Wegovy and promising results from a higher-dose version may enhance future market share.
- PDD Holdings' Resilience: PDD Holdings' stock has dropped 17% this year, currently trading around $95, yet despite facing tariffs and trade uncertainties, sales for the last three months of 2025 increased by 12% to $17.7 billion, demonstrating the company's resilience, with potential for recovery if trade conditions improve.
- Investment Opportunities: Pfizer, Novo Nordisk, and PDD Holdings are all trading below their projected future earnings, with Pfizer at a P/E of 9, Novo Nordisk at 14, and PDD Holdings at just 8, presenting attractive buying opportunities for long-term investors amid current undervaluation.
See More
Eli Lilly to Participate in Strategic Decisions Conference
- Conference Participation: Eli Lilly will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026, where Chief Scientific and Product Officer Daniel M. Skovronsky, M.D., Ph.D., will engage in a fireside chat at 1:30 p.m., showcasing the company's latest advancements in science and product development.
- Live Webcast: The event will be available via a live audio webcast on Lilly's investor website, ensuring global investors can access real-time strategic information, thereby enhancing transparency and investor confidence.
- Replay Availability: A replay of the presentation will be accessible on the same website for approximately 90 days post-event, allowing investors who could not attend live to review key content, further improving information accessibility.
- Company Mission: Eli Lilly is committed to leveraging biotechnology, chemistry, and genetic medicine to address significant global health challenges, driving the development of innovative medicines to improve the quality of life for tens of millions, reflecting its leadership in the healthcare sector.
See More
Trump Administration Expands TrumpRx with Generic Medications
- Platform Expansion: The Trump administration announced the addition of over 600 generic medications to the TrumpRx website, aiming to lower prescription drug costs in the U.S. by providing transparent pricing and enhancing consumer choice.
- New Tools Launched: The platform now features tools that connect patients with the lowest-priced pharmacies in their area and offers home delivery options for prescriptions, improving user experience and facilitating easier access to medications.
- Partnerships Established: The administration is partnering with industry players like Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx to promote direct-to-consumer drug sales, ensuring price transparency for consumers.
- User Engagement and Savings: Since its launch, TrumpRx has recorded over 10 million visits and saved Americans more than $400 million, although it remains unclear if all patients will benefit from this platform compared to traditional purchasing methods.
See More
US Supreme Court Rejects Eli Lilly's Challenge to Whistleblower Law
- Legal Challenge Denied: The US Supreme Court's refusal to hear Eli Lilly's challenge to the whistleblower law could significantly impact compliance costs and legal risks within the pharmaceutical industry.
- Origin of the Case: This challenge originated in 2014 when pharmacist and lawyer Ronald Streck accused Lilly of failing to pay full drug rebates to Medicaid, resulting in a $183 million judgment, highlighting the regulatory scrutiny faced by pharmaceutical companies.
- Legal Consequences: With the Supreme Court's decision, Lilly may encounter an increase in whistleblower lawsuits, raising its legal compliance costs and potentially affecting its future financial performance and market confidence.
- Industry Implications: This ruling may prompt other pharmaceutical companies to pay closer attention to compliance issues, particularly regarding drug pricing and rebate transparency, thereby influencing operational models and competitive strategies across the industry.
See More
Healthcare Stocks Rise Slightly on NYSE
- Healthcare Index Increase: The NYSE Healthcare Index rose by 0.4% on Monday afternoon, indicating a rebound in market confidence towards the healthcare sector, likely influenced by optimistic investor expectations regarding future healthcare policies.
- Market Trend Analysis: The upward trend in healthcare stocks suggests that despite economic uncertainties, investors remain bullish on the long-term growth potential of the healthcare industry, particularly in the context of new drug development and an aging population.
- Improved Investor Sentiment: The stable performance of healthcare stocks has led to improved investor sentiment, which may result in increased capital inflows into the sector, further driving the rise in healthcare stocks.
- Industry Outlook: The ongoing growth in the healthcare sector is likely to attract more investor attention, especially with the dual support of policy backing and technological innovation, indicating that more investment opportunities are expected to emerge in the future.
See More
Pharmaceutical Giants' Acquisition Targets Analysis
- Viking Therapeutics Highlights: Viking Therapeutics' VK2735, a dual GLP-1/GIP agonist, has enrolled over 4,500 patients in Phase 3 ahead of schedule, with oral formulations achieving a 12.2% body weight reduction in 13 weeks, making it a strategically attractive acquisition target with a market cap of $3.69 billion and $706 million in cash.
- Scholar Rock's Market Potential: Scholar Rock's muscle-targeted therapy apitegromab is expected to launch in Europe in H2 2026, already partnered with Novo Nordisk, with a market cap of $5.55 billion and an analyst target price of $57.73, highlighting its significance in the GLP-1 landscape.
- Verve Therapeutics' Outlook: Verve Therapeutics' VERVE-102, a single-dose gene-editing PCSK9 therapy, achieved a 53% mean LDL-C reduction in the Heart-2 Phase 1b trial, with Lilly holding an opt-in that may lead to outright acquisition, showcasing its potential in cardiovascular disease treatment.
- Market Competition Dynamics: Eli Lilly and Novo Nordisk are aggressively acquiring early-stage therapeutics to maintain GLP-1 market dominance, with Lilly's recent four acquisitions indicating its expansion strategy, despite Novo facing pricing pressures and declining sales challenges.
See More
Three Undervalued Stocks to Consider Now
- Pfizer's Current Status: Pfizer's stock is currently priced around $25, and despite a 1% increase this year, investors have seen a 37% decline over the past five years due to slowing growth and patent expirations; however, the company is actively expanding its pipeline through acquisitions like Metsera, which could improve future performance.
- Novo Nordisk's Challenges: Novo Nordisk's GLP-1 drugs, Wegovy and Ozempic, have been approved and are generating significant revenue, but rising competition has led to a 4% decline in sales in the first quarter; nevertheless, strong demand for Wegovy and promising results from a higher-dose version may enhance future market share.
- PDD Holdings' Resilience: PDD Holdings' stock has dropped 17% this year, currently trading around $95, yet despite facing tariffs and trade uncertainties, sales for the last three months of 2025 increased by 12% to $17.7 billion, demonstrating the company's resilience, with potential for recovery if trade conditions improve.
- Investment Opportunities: Pfizer, Novo Nordisk, and PDD Holdings are all trading below their projected future earnings, with Pfizer at a P/E of 9, Novo Nordisk at 14, and PDD Holdings at just 8, presenting attractive buying opportunities for long-term investors amid current undervaluation.
See More
Eli Lilly to Participate in Strategic Decisions Conference
- Conference Participation: Eli Lilly will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026, where Chief Scientific and Product Officer Daniel M. Skovronsky, M.D., Ph.D., will engage in a fireside chat at 1:30 p.m., showcasing the company's latest advancements in science and product development.
- Live Webcast: The event will be available via a live audio webcast on Lilly's investor website, ensuring global investors can access real-time strategic information, thereby enhancing transparency and investor confidence.
- Replay Availability: A replay of the presentation will be accessible on the same website for approximately 90 days post-event, allowing investors who could not attend live to review key content, further improving information accessibility.
- Company Mission: Eli Lilly is committed to leveraging biotechnology, chemistry, and genetic medicine to address significant global health challenges, driving the development of innovative medicines to improve the quality of life for tens of millions, reflecting its leadership in the healthcare sector.
See More
